IDSA’s “Science Speaks”: Dolutegravir results in low-resource setting highlight benefits
Antigone Barton, senior editor and writer at “Science Speaks,” discusses findings from a study examining the use of dolutegravir-based treatments for HIV in a low-resource setting. Barton notes, “[F]indings from the first study … show use of the drug to be cost effective, as well as safe and extremely effective in suppressing viral loads quickly and maintaining viral suppression below detectable levels” (9/12).